Home › Esophageal Adenocarcinoma › Iowa
Esophageal Adenocarcinoma clinical trials in Iowa
5 studies for Esophageal Adenocarcinoma are looking for participants at sites in Iowa.
Cities in Iowa
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- Saint Anthony Regional Hospital, Carroll
- Mercy Hospital, Cedar Rapids
- and 8 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- and 12 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT05677490Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- University of Iowa Hospitals and Clinics, Iowa City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06324357A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Local Institution - 0268, Iowa City
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07221149Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Waukee
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07431281From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.